Beyond the well-explored proposition of protein aggregation
or
amyloidosis as the central event in amyloidogenic diseases like Alzheimer’s
Disease (AD), and Type 2 Diabetes Mellitus (T2Dm); there are alternative
hypotheses, now becoming increasingly evident, which suggest that
the small biomolecules like redox noninnocent metals (Fe, Cu, Zn,
etc.) and cofactors (Heme) have a definite influence in the onset
and extent of such degenerative maladies. Dyshomeostasis of these
components remains as one of the common features in both AD and T2Dm
etiology. Recent advances in this course reveal that the metal/cofactor-peptide
interactions and covalent binding can alarmingly enhance and modify
the toxic reactivities, oxidize vital biomolecules, significantly
contribute to the oxidative stress leading to cell apoptosis, and
may precede the amyloid fibrils formation by altering their native
folds. This perspective highlights this aspect of amyloidogenic pathology
which revolves around the impact of the metals and cofactors in the
pathogenic courses of AD and T2Dm including the active site environments,
altered reactivities, and the probable mechanisms involving some highly
reactive intermediates as well. It also discusses some in
vitro metal chelation or heme sequestration strategies which
might serve as a possible remedy. These findings might open up a new
paradigm in our conventional understanding of amyloidogenic diseases.
Moreover, the interaction of the active sites with small molecules
elucidates potential biochemical reactivities that can inspire designing
of drug candidates for such pathologies.